<- Go Home
Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Market Cap
$504.9M
Volume
221.3K
Cash and Equivalents
$103.8M
EBITDA
-$100.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$74.9M
Profit Margin
N/A
52 Week High
$37.27
52 Week Low
$12.97
Dividend
N/A
Price / Book Value
1.89
Price / Earnings
-7.63
Price / Tangible Book Value
1.89
Enterprise Value
$245.7M
Enterprise Value / EBITDA
-2.53
Operating Income
-$103.2M
Return on Equity
31.41%
Return on Assets
-20.66
Cash and Short Term Investments
$269.0M
Debt
$9.9M
Equity
$264.9M
Revenue
N/A
Unlevered FCF
-$46.5M
Sector
Biotechnology
Category
N/A